|Bid||0.00 x 38800|
|Ask||0.00 x 3100|
|Day's Range||1.66 - 1.69|
|52 Week Range||1.38 - 4.21|
|PE Ratio (TTM)||1.85|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A South Carolina jury on Friday could not agree on a verdict in a case of a woman whose family said her long-term use of Johnson & Johnson's Baby Powder led to her death from asbestos-related cancer, resulting in a mistrial. The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that center around allegations that the company's talc-based powder contained asbestos. "We're disappointed the jury did not reach a unanimous verdict for Johnson & Johnson," the company said in a statement emailed to Reuters.
Wall Street is on pins and needles waiting for Amazon to announce its plans to get into the healthcare space. If Amazon opts to get into the pharmacy space, the financial impact to Walgreens and Rite Aid ...
As Rite Aid and Albertsons work through their merger, they are touting growth potential and the ability to compete with retailers Walmart, CVS Health, Walgreens Boots Alliance and grocer Kroger on a national level. Executives Tuesday said there is while tapping new markets for health and drug benefits, particularly for seniors insured by Medicare in California where both have strong brands. Combined, Albertsons and Rite Aid say the proposed new company will have $82 billion in sales, ranking fifth behind Walmart, which at No. 1 will be more than triple its size with more than $300 billion in annual revenue.
J&J said that its widely-used baby powder never contained asbestos, a known carcinogen linked to mesothelioma. The case also names as a defendant a local unit of Rite Aid, one of the largest U.S. drugstore chains, which allegedly sold the baby powder used by the woman. The case marked the first time a drugstore was involved in a talcum powder liability trial and a lawyer for the company, Sarah Johnston, said there was no reason for Rite Aid to be part of the suit.
J&J said that its widely-used baby powder never contained asbestos, a known carcinogen linked to mesothelioma. The case also names as a defendant a local unit of Rite Aid (RAD.N), one of the largest U.S. drugstore chains, which allegedly sold the baby powder used by the woman. The case marked the first time a drugstore was involved in a talcum powder liability trial and a lawyer for the company, Sarah Johnston, said there was no reason for Rite Aid to be part of the suit.
Moody's rating action reflects a base expected loss of 0.0% of the current pooled balance, compared to 1.5% at Moody's last review. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.
CVS Health Corp (NYSE:CVS) reported Q1 earnings, the shares are back to where they started, despite a bit of a roller-coaster ride. The Woonsocket, Rhode Island-based healthcare services company beat earnings estimates but missed on revenue. With its pending acquisition of Aetna, CVS starts a new chapter (maybe a whole book).
Moody's rating action reflects a base expected loss of 0% of the current pooled balance, the same as at Moody's last review. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating.
Buildings are reflected in the window of a CVS Health Corp. store in downtown Los Angeles, California, U.S., on Friday, Oct. 27, 2017. Fred’s Inc. said CVS Health is buying its specialty pharmacy business EntrustRx for $40 million amid the retailer’s effort to execute a financial turnaround. “One of Fred’s top priorities for 2018 has been to monetize non-core assets and we are pleased to have reached an agreement for the sale of EntrustRx,” Fred’s interim CEO Joseph Anto said in a statement Monday afternoon.
The Rhode Island–based CVS Health (CVS) reported its results for 1Q18 on May 2. The pharmacy giant reported an earnings beat for the quarter but failed to meet top-line expectations.
Fred's Pharmacy on Friday, May 4, 2018 said planned to sell its specialty pharmacy business and look at various options for its retail pharmacies. Fred’s confirmed Friday plans to sell the company’s specialty pharmacy business as part of a turnaround plan. Potential bidders could include larger pharmacy chains CVS Health, Walgreens Boots Alliance, and Rite Aid that are already reporting specialty pharmacy as a key driver of overall growth as more patients need help with management and related support for the complex medications they take for their chronic and sometimes rare conditions.
Fred's Inc. is evaluating options for its retail pharmacy portfolio. Fred’s is evaluating options for its retail pharmacy portfolio and “actively pursuing a sale” of its specialty pharmacy business, the retailer said Friday, a year after the company failed to buy hundreds of Rite Aids. “Some of the strategic transactions we are actively pursuing include a sale of our specialty pharmacy business and portions of our vast real estate portfolio," Antos added.
Fred's CEO Michael K. Bloom has resigned as CEO after less than two years in the top job and a failed attempt to buy hundreds of Rite Aids.
Fred's Inc, which was forced to abandon its bid to acquire certain stores of drug retailer Rite Aid Corp, said on Friday its Chief Executive Officer Michael Bloom has resigned. The discount store operator said Chief Financial Officer Joseph Anto took over from Bloom as the interim CEO on April 24. In June, Fred's was forced to scrap its bid for 1,200 Rite Aid Corp stores, a deal that was chalked out so that drugstore chain Walgreens Boots Alliance Inc could win antitrust approval for its purchase of Rite Aid.
Moody's Investors Service, ("Moody's") today assigned a B1 Corporate Family Rating and B1-PD probability of default rating to Albertsons Companies, Inc. ("Albertsons"). Moody's also ...
Rite Aid’s (RAD) management provided guidance for fiscal 2019 in its fiscal 4Q18 report. Management believes the company will benefit from generic drug purchasing efficiencies, a more stable reimbursement rate environment, Walgreens’s deal-related TSA (Transportation Security Administration) fees, and the company’s ongoing initiatives in fiscal 2019.
As we saw in the previous part of this series, Rite Aid (RAD) reported an 8.6% YoY (year-over-year) decline in its fiscal 4Q18 revenues from continuing operations to $5.4 billion. Its Retail Pharmacy segment, which includes prescription drugs, health and beauty products, and personal care items, saw its revenue fall 10.1% to $4 billion. Same-store sales from continuing operations fell 1.7% YoY during the quarter, driven by a 2.3% decline in pharmacy sales and a 0.6% fall in front-end sales.
Rite Aid (RAD) reported its fiscal 4Q18 results after the market closed on Thursday, April 12, 2018. Its top line fell 8.6% YoY (year-over-year) to $5.4 billion, missing the average consensus expectation by $180 million.
CVS (CVS), which is an American retail pharmacy and healthcare company, was the S&P 500’s second-highest performer on April 16. After gaining for three consecutive trading days, CVS opened higher on Monday and surged to four-week high price levels.
On Thursday, April 12, 2018, Rite Aid (RAD) reported its results for fiscal 4Q18 and fiscal 2018. The results relate to the three-month and 12-month period that ended March 3, 2018.
Despite the threat of Amazon entering the pharmacy business, Walgreens, CVS and Rite Aid see corner locations and bricks and mortar expansions as a consumer's entry point for health access.